ArticleGynecologic oncology reports2026
Highlighting the molecular refinement of NSMP endometrial cancer in a case of mesonephric-like adenocarcinoma.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 2025 ESGO/ESTRO/ESP guideline for endometrial carcinoma (EC) integrates molecular classification into clinical decision-making and, for the first time, recommends the subdivision of carcinomas with no specific molecular profile (NSMP) according to estrogen receptor (ER) status and histological grading. However, NSMP carcinomas remain a highly heterogeneous subgroup, posing challenges in terms of diagnosis and therapy. Case presentation: We report the case of a 71-year-old female patient with low-grade NSMP EC. Due to ER-negativity and strong L1 cell adhesion molecule (L1CAM) expression, the German/Austrian/Swiss S3 guideline at that time required comprehensive histopathological reassessment, which reclassified the tumor as mesonephric-like adenocarcinoma. Extended molecular profiling further identified a Conclusion: This case demonstrates molecular classification of an unusual histological type of EC exhibiting an extremely short-term risk of early distant metastasis and its implication on aggressive adjuvant therapeutical approach. It, furthermore, exemplifies the pronounced heterogeneity of the NSMP subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.